SGLT2 inhibitors significantly reduced the risk of all‐cause death in the overall HF cohort compared with placebo [HR: 0.89 (0.82–0.96); P = 0.004; I2 = 0%]. The gene discussed is SLC5A2; the disease is hydrops fetalis.